Stability‐Enhanced Therapeutic Artificial Cells Based on a Lipid–Polymer Integrated Architecture
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.1082242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Zongyou Pan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eye Center & Department of Orthopedic Surgery, School of Medicine, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Artificial Cells, Polymers, Lipids. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Startup Package of Zhejiang University.
Abstract (Originalsprache)
Current artificial cells often lack robustness in the face of the complex physiological milieu. Additionally, the strategies for mimicking natural cargo exchange mostly rely on biological techniques, which involve integrating native channel proteins or adopting intact natural cell membranes. Herein, we propose a rational chemical design strategy to construct artificial mini cells (MCs) based on a lipid–polymer integrated architecture. Our MCs show three key merits, including robust structural stability, controllable metabolic reactions, and convenient surface functionalization for diverse biomedical applications. MCs adopt a lipid–polymer integrated architecture, where a cross‐linked zwitterionic polymer in situ grown on the phospholipid membrane acts as the conceptually synthesized cytoskeleton mimic, ensuring structural stability and easy functionalization. Azobenzene‐gated lipids are incorporated to act as light‐responsive channel protein mimics, enabling spatiotemporal regulation of membrane permeability and metabolic reactions. As a proof of concept, therapeutic artificial MCs with tumor tropism, surface‐immobilized aPDL1 proteins, and internally encapsulated glucose oxidase–catalase (GOx–Cat) multi‐enzyme system were rationally designed, named aPDL1‐Tt‐MC(GOx + Cat). aPDL1‐Tt‐MC(GOx + Cat)s possess zwitterionic ionizable pyridine carboxybetaine moieties for tumor tropism, the GOx–Cat system for light‐controlled glucose‐to‐O 2 conversion to drive deep tumor infiltration, and surface‐immobilized aPDL1 to block PD‐1/PD‐L1 recognition for enhanced antitumor efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Center & Department of Orthopedic Surgery, School of Medicine, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China.
- State Key Laboratory of Advanced Drug Delivery and Release Systems, Institute of Pharmaceutics, School of Pharmacy, Zhejiang University, Hangzhou, China.
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
- Zhejiang Key Laboratory of Anti-Cancer Drug Research, School of Pharmacy, Zhejiang University, Hangzhou, China.
ORCID-Profile: Zongyou Pan, Yu Zhao
Förderung
- Startup Package of Zhejiang University
Zitieren
APA
Pan, Z., Zhao, M., Wang, Z., Li, Z., Wu, H., Xu, K., & Zhao, Y. (2026). Stability‐Enhanced Therapeutic Artificial Cells Based on a Lipid–Polymer Integrated Architecture. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.1082242
Vancouver
Pan Z, Zhao M, Wang Z, Li Z, Wu H, Xu K, et al. Stability‐Enhanced Therapeutic Artificial Cells Based on a Lipid–Polymer Integrated Architecture. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.1082242
BibTeX
@article{Pan2026,
author = {Pan, Zongyou and Zhao, Mengqi and Wang, Zeyu and Li, Zilu and Wu, Honghui and Xu, Kaiwang and Zhao, Yu},
title = {Stability‐Enhanced Therapeutic Artificial Cells Based on a Lipid–Polymer Integrated Architecture},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.1082242}
}
EUVIMED